AROS Is a Significant Biomarker for Tumor Aggressiveness in Non-cirrhotic Hepatocellular Carcinomaopen access
- Authors
- Kwon, Jung-Hee; Ahn, Keun Soo; Moon, Young Ho; Park, Jin Young; Wang, Hee Jung; Choi, Kwan Yong; Kim, Gundo; Joh, Jae Won; Lee, Kyeong Geun; Kang, Koo Jeong
- Issue Date
- Sep-2015
- Publisher
- KOREAN ACAD MEDICAL SCIENCES
- Keywords
- Carcinoma; Hepatocellular; Prognosis; Biological Markers
- Citation
- JOURNAL OF KOREAN MEDICAL SCIENCE, v.30, no.9, pp.1253 - 1259
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- JOURNAL OF KOREAN MEDICAL SCIENCE
- Volume
- 30
- Number
- 9
- Start Page
- 1253
- End Page
- 1259
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/156453
- DOI
- 10.3346/jkms.2015.30.9.1253
- ISSN
- 1011-8934
- Abstract
- Despite a low risk of liver failure and preserved liver function, non-cirrhotic hepatocellular carcinoma (HCC) has a poor prognosis. In the current study, we evaluated an active regulator of SIRT1 (AROS) as a prognostic biomarker in non-cirrhotic HCC. mRNA levels of AROS were measured in tumor and non-tumor tissues obtained from 283 non-cirrhotic HCC patients. AROS expression was exclusively up-regulated in recurrent tissues from the non-cirrhotic HCC patients (P = 0.015) and also in tumor tissues irrespective of tumor stage (P < 0.001) or BCLC stage (P < 0.001). High mRNA levels of AROS were statistically significantly associated with tumor stage (P < 0.001), BCLC stage (P = 0.007), alpha fetoprotein (AFP) level (P = 0.013), microvascular invasion (P = 0.001), tumor size (P = 0.036), and portal vein invasion (P = 0.005). Kaplan-Meir curve analysis demonstrated that HCC patients with higher AROS levels had shorter disease-free survival (DFS) in both the short-term (P < 0.001) and long-term (P = 0.005) compared to those with low AROS. Cox regression analysis demonstrated that AROS is a significant predictor for DFS along with large tumor size, tumor multiplicity, vascular invasion, and poor tumor differentiation, which are the known prognostic factors. In conclusion, AROS is a significant biomarker for tumor aggressiveness in non-cirrhotic hepatocellular carcinoma.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 외과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/156453)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.